D
Crinetics Pharmaceuticals, Inc. CRNX
$41.20 $1.122.79% NASDAQ
Recommendation
Prev Close
$40.08
Volume
462,083
Avg Vol (90D)
1,254,965
Market Cap
$3.77B
Dividend & Yield
--
52-Week Range
$24.10 - $62.53
P/E (TTM)
--
EPS (TTM)
-$4.11
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
10/23/2025 - Globe Newswire
Crinetics Pharmaceuticals (CRNX): Taking Stock of Valuation After Recent Volatility and Rebound
10/23/2025 - Simply Wall St
First Week of June 2026 Options Trading For Crinetics Pharmaceuticals (CRNX)
10/21/2025 - Stock Options Channel
Crinetics Pharmaceuticals (CRNX, $42.45) Stochastic Oscillator left the oversold zone on October 20, 2025
10/21/2025 - Tickeron - Stocks
Crinetics Pharmaceuticals (CRNX, $42.31) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 16, 2025
10/17/2025 - Tickeron - Technical Analysis
Crinetics Pharmaceuticals (CRNX, $44.43) entered Uptrend as Momentum indicator ascends above 0 level on Oct 13, 2025
10/14/2025 - Tickeron - Technical Analysis
Crinetics Pharmaceuticals (CRNX, $44.93) RSI Indicator left the overbought zone on October 10, 2025
10/11/2025 - Tickeron - Stocks
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule ...
10/10/2025 - GuruFocus
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule ...
10/10/2025 - GuruFocus
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10/2025 - Globe Newswire
Crinetics Pharmaceuticals (CRNX, $45.76) Stochastic Oscillator left the overbought zone on October 09, 2025
10/10/2025 - Tickeron - Stocks
Crinetics Pharmaceuticals' (CRNX) "Sell (D-)" Rating Reiterated at Weiss Ratings
10/10/2025 - MarketBeat
Why Crinetics Pharmaceuticals (CRNX) Is Up 6.8% After FDA Approval of First Oral Acromegaly Therapy
10/9/2025 - Simply Wall St
Crinetics Pharmaceuticals (CRNX, $44.43) RSI Indicator left the overbought zone on October 08, 2025
10/9/2025 - Tickeron - Stocks
The volume for Crinetics Pharmaceuticals stock increased for one day, resulting in a record-breaking daily growth of 298% of the 65-Day Volume Moving Average
10/8/2025 - Tickeron - Stocks
14 Biotech Stocks with High Potential
10/7/2025 - Insider Monkey
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
10/6/2025 - GuruFocus
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
10/6/2025 - Globe Newswire
Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 15% Share Price Climb This Month
10/6/2025 - Simply Wall St
Dana Pizzuti Sells 5,000 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock
10/5/2025 - Ticker Report
Crinetics Pharmaceuticals Shares Swing After Data on Paltusotine and Valuation Metrics Scrutinized
10/4/2025 - Simply Wall St
Dana Pizzuti Sells 5,000 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock
10/4/2025 - MarketBeat
Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Sells 5,000 Shares of Stock
10/3/2025 - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) CEO Sells $180,000.00 in Stock
10/3/2025 - Ticker Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $87.00
10/3/2025 - Ticker Report
Income Statement
Total Revenue (TTM)
$1.39M
EBITDA (TTM)
-$419.62M
EBIT (TTM)
-$423.06M
Net Income (TTM)
-$369.83M
Balance Sheet
Total Assets (Q)
$1.29B
Total Debt (Q)
$49.94M
Total Liabilities (Q)
$118.05M
Book Value Per Share (Q)
$12.45
Cash Flow
Cash from Operations (TTM)
-$301.80M
Cash from Investing (TTM)
-$569.49M
Cash from Financing (TTM)
$622.86M
Net Change in Cash (TTM)
-$248.44M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
1.69
7-Day Total Return
-6.66%
30-Day Total Return
21.21%
60-Day Total Return
44.14%
90-Day Total Return
33.58%
Year to Date Total Return
-20.06%
1-Year Total Return
-29.84%
2-Year Total Return
38.66%
3-Year Total Return
142.55%
5-Year Total Return
230.21%
52-week Low
Apr 09, 2025 - $24.10
52-week High
Nov 14, 2024 - $62.53
Valuation
Market Cap
$3.77B - Mid Cap
Enterprise Value
$2.63B
Price/Sales (TTM)
2,708.11
Price/Book (Q)
3.22
Dividends and Shares
Shares Outstanding
93.79
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.crinetics.com
Phone Number
858 450 6464
Address
6055 Lusk Boulevard
San Diego, CA 92121
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and... more
NASDAQ 10/24/2025 3:46PM Eastern Quotes delayed